ArticleBMC cancer2025
Silencing TMEM105 suppresses gastric cancer cell growth and migration via proliferation-associated pathways.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNumerous studies in the field of cancer indicate that long non-coding RNAs (lncRNAs) play a significant role in the development and malignancy of various cancers. In this study, the expression changes of TMEM105 in gastric cancer (GC) and its association with malignancy were examined.
methodsIn the in silico section, TMEM105 expression in GC and its correlation with patient prognosis were analyzed using publicly available datasets. Using WGCNA analysis on TCGA data, modules and potential pathways associated with TMEM105 were identified. Expression changes of TMEM105 in GC tissues compared with adjacent healthy tissues were analyzed by RT-qPCR. The expression level of TMEM105 in GC cell lines, including AGS and MKN-45, was modulated using siRNA. The relationship between TMEM105 expression and malignant characteristics, including cell proliferation, migration, and colony formation, was examined in these cell lines.
resultsTMEM105 was significantly upregulated in public datasets, including TCGA, GSE19826, and GSE54129. TMEM105 expression was associated with advanced disease stage and poor prognosis. WGCNA analysis revealed that TMEM105 expression clustered with genes related to cell proliferation, such as E2F target genes, within the same module. Silencing TMEM105 reduced the viability of GC cell lines and decreased mRNA expression of proliferation-related genes, including E2F1, Cyclin D1, and Ki-67. Silencing TMEM105 markedly reduced migration rates in GC cells. Moreover, TMEM105 expression affected the colony-forming ability of these cell lines.
conclusionHigh TMEM105 expression in GC is associated with poorer patient outcomes. It appears to influence cellular proliferation and contribute to the development and malignancy of gastric carcinoma. Consequently, TMEM105 could be a valuable therapeutic and prognostic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.